Cartagenia and Interactive Biosoftware have signed an agreement allowing Cartagenia to integrate IB's Alamut gene visualization software into its BenchLab, a web-based software tool for interpreting genomic variation in routine diagnostics.
The combined solution will merge BenchLab’s variant data filtering, interpretation, and management capabilities with Alamut’s annotation and visualization functionalities. It will let users assess candidate variants in context of phenotype as well as integrate their findings and conclusions with a lab or hospital’s laboratory information management system or electronic health record system.
Under the terms of the agreement, Cartagenia and IB will each market the combined solution to their respective customers, while continuing to sell their own products independently.
Andre Blavier, IB’s CEO, described the alliance between the two companies as a natural fit.
With the integration deal, “our Alamut solution is now extended with capabilities which were previously unavailable to us, such as patient database management, massively parallel variant filtering, and advanced lab reporting," Blavier said.
Furthermore, many BenchLab customers already use IB’s Alamut, Herman Verrelst, Cartagenia’s CEO, noted.
“The high level of automation and the lab-validated variant filtration pipelines in BenchLab are perfectly complemented by the Alamut gene browser that allows lab technicians to visualize specific variants of interest,” he said in a statement. “A technical integration of the two systems provides a single workflow experience.”